When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

doi:10.1186/1546-0096-6-S1-P40

Pediatric Rheumatology

Volume 6
Suppl 1

Viewing options:

Abstract
Full text
PDF (133KB)

Related literature:

Articles citing this article
on Google Scholar
Other articles by authors
on Google Scholar

Prince FHM
Twilt M
Simon SCM
van Rossum MAJ
Armbrust W
Hoppenreijs EPAH
Kamphuis SSM
van Santen-Hoeufft M
Koopman-Keemink Y
Wulffraat N
ten Cate R
van Suijlekom-Smit LWA

on PubMed

Prince FHM
Twilt M
Simon SCM
van Rossum MAJ
Armbrust W
Hoppenreijs EPAH
Kamphuis SSM
van Santen-Hoeufft M
Koopman-Keemink Y
Wulffraat N
ten Cate R
van Suijlekom-Smit LWA
Related articles/pages
on Google

on Google Scholar

Tools:

Post to:

This article is part of the supplement: 15th Paediatric Rheumatology European Society (PreS) Congress .

Poster presentation

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

FHM Prince¹, M Twilt¹, SCM Simon¹, MAJ van Rossum³, W Armbrust⁴, EPAH Hoppenreijs⁵, SSM Kamphuis¹, M van Santen-Hoeufft⁶, Y Koopman-Keemink⁷, N Wulffraat⁸, R ten Cate² and LWA van Suijlekom-Smit¹

¹Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands

²Leiden University Medical Centre, Leiden, Netherlands

³AMC Emma Children's Hospital, Amsterdam, Netherlands

⁴UMCG Beatrix Children's Hospital, Groningen, Netherlands

⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

⁶Academic Hospital Maastricht, Maastricht, Netherlands

⁷Hagaziekenhuis Juliana Children's Hospital, Den Haag, Netherlands

⁸Utrecht MC Wilhelmina Children's Hospital, Utrecht, Netherlands

corresponding author email

from 15^thPaediatric Rheumatology European Society (PreS) Congress
London, UK. 14–17 September 2008

Pediatric Rheumatology 2008, 6(Suppl 1):P40doi:10.1186/1546-0096-6-S1-P40


Published:	15 September 2008

First paragraph (this article has no abstract)

The aim of etanercept therapy in juvenile idiopathic arthritis (JIA) is to achieve disease remission. However, little is known about when or how to stop etanercept when this aim is reached. Our objective was to describe characteristics and disease course of JIA patients who discontinued etanercept because of a sustained good clinical response.